Clinical Read2026-06-30
DNL758 (CNS-penetrant RIPK1 inhibitor)
Denali TherapeuticsDNLI
- Indication
- Lupus nephritis, Cutaneous lupus erythematosus, Ulcerative colitis
- Stage
- Phase 2
- Event
- Phase 2 Data readout
- Details
Collab w/ Sanofi. 01/2023- Initiated enrollment in patients w/ UC. Completed CLE part. 10/23- CLE study discontinued, did not meet the endpoint. 02/27/24- Study ongoing for UC. 11/06/25:- PR No update. 02/26/26:- Ph2 ulcerative colitis study of eclitasertib ongoing; results expected in H1 2026. 05/07/26:- PR No update.
Financial Snapshot
Market Cap
$3.1B
Price
$20.79